TBPH 17.07 Theravance Biopharma Inc. $TBPH Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
TBPH 17.07 Theravance Biopharma Inc. $TBPH Hit a 52 week low of 15.67 Currently at 17.07 -0.37 -2.12% With a day low of 15.67 and a total volume of 281,500.

TBPH Theravance Biopharma Inc. Recent Headline News

Theravance Biopharma, Inc. Reports Third Quarter 2014 Financial Results
Marketwired - Thu Nov 06, 3:16PM CST
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" , through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share. Cash, cash equivalents, and marketable securities totaled $350.4 million as of September 30, 2014.
TBPH: 17.07 (-0.37)

Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Marketwired - Mon Nov 03, 3:08PM CST
Theravance Biopharma (NASDAQ: TBPH), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today announced positive results from the first three cohorts of Study 0110, a Phase 1 proof-of-concept study of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus infection (HCV).
TBPH: 17.07 (-0.37)

Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.95 (+0.83), TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)

Theravance Biopharma, Inc. to Report Third Quarter 2014 Financial Results on November 6, 2014
Marketwired - Thu Oct 30, 3:20PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" announced today, through its US operating subsidiary, Theravance Biopharma US, Inc., that it will release financial results for the period ended September 30, 2014, after the market close on Thursday, November 6, 2014.
TBPH: 17.07 (-0.37)

Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)

Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 110.81 (+0.08), MRK: 59.34 (+0.08), OPHT: 41.26 (+0.14), TBPH: 17.07 (-0.37)

Theravance Biopharma Provides VIBATIV(R) (telavancin) Product Update
Marketwire - Tue Sep 09, 7:05AM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" today provided a product update for VIBATIV(R) (telavancin), the Company's proprietary FDA-approved bactericidal, once-daily, injectable lipoglycopeptide antibiotic. The Company detailed plans for additional VIBATIV clinical studies, its strategy for increasing the scope of US commercial efforts and new study analyses presented at recent scientific conferences underscoring VIBATIV's in vitro potency and activity. Today's announcement is being made in conjunction with the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being held September 5-9, 2014 in Washington D.C.
TBPH: 17.07 (-0.37)

Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Dose-Ranging Study of its Investigational LAMA, TD-4208, for the Treatment of COPD
Marketwire - Mon Sep 08, 3:05PM CDT
Theravance Biopharma (NASDAQ: TBPH), through its US operating subsidiary, Theravance Biopharma US, Inc., today announced positive top-line results from its Phase 2b dose-ranging study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA) in development for the treatment of chronic obstructive pulmonary disease (COPD). The study evaluated four doses of TD-4208 (44, 88, 175 and 350 mcg) and placebo, administered once daily for 28 days in a double-blind, parallel group study in a total of 355 patients with moderate-to-severe COPD.
TBPH: 17.07 (-0.37)

Drug M&A Boom Driven By Long-Term Trends: PwC
at Investor's Business Daily - Wed Sep 03, 3:22PM CDT
If you've been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released...
MNK: 91.06 (-3.49), JNJ: 108.20 (-0.81), CG: 28.94 (+0.68), TBPH: 17.07 (-0.37), THRX: 14.27 (-0.13), BMY: 58.32 (-0.14)

Theravance Biopharma to Present at Investor Conferences in September 2014
Marketwire - Thu Aug 21, 3:05PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014:
TBPH: 17.07 (-0.37)

Theravance Biopharma, Inc. Reports Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 3:06PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" today reported financial results for the second quarter 2014, and provided a corporate update. Revenue for the second quarter of 2014 was $3.0 million. Net loss for the second quarter of 2014 was $58.2 million or $1.83 per share. Cash, cash equivalents, and marketable securities totaled $387.4 million as of June 30, 2014.
TBPH: 17.07 (-0.37)

Theravance (THRX) Incurs Narrower-than-Expected Loss in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:10AM CDT
Theravance (THRX) incurred a loss of 18 cents in the quarter.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)

Theravance Reports Second Quarter 2014 Financial Results
Marketwire - Wed Aug 06, 3:08PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended June 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on September 18, 2014 to stockholders of record as of the close of business on August 28, 2014. Royalties earned in the second quarter of 2014 were $3.3 million, which were partially offset by amortization of intangible assets of $2.6 million resulting in net royalty revenues of approximately $0.7 million from Glaxo Group Limited (GSK) related to net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from GSK. Net loss for the second quarter of 2014 was $63.6 million or $0.57 per diluted share. Cash and cash equivalents, short-term investments, marketable securities and current restricted cash totaled $383.1 million as of June 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)

Theravance, Inc. Appoints Michael W. Aguiar as President and Chief Executive Officer
Marketwire - Wed Aug 06, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) ("Theravance" or "Company" today announced that its Board of Directors has appointed Michael W. Aguiar as President and Chief Executive Officer of the Company effective August 15, 2014 and as a member of the Board of Directors effective immediately. Mr. Aguiar plans to continue to serve as Theravance's Senior Vice President and Chief Financial Officer until his replacement is identified and appointed. Mr. Aguiar will replace Rick E Winningham who has resigned as Chief Executive Officer of Theravance effective August 15, 2014. Mr. Winningham will remain Chairman of the Board of Directors of Theravance, Inc. and will transition to full time Chief Executive Officer of Theravance Biopharma, Inc. ("Theravance Biopharma" as of August 15, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)

DNAnexus Appoints David Shaywitz as Chief Medical Officer
Business Wire - Tue Aug 05, 6:30AM CDT
DNAnexus, a leader in enterprise solutions for networked genome informatics and data management, today announced the expansion of its senior leadership team with the appointment of David Shaywitz, M.D., Ph.D. as the company's first Chief Medical Officer. Shaywitz joins DNAnexus from Theravance Biopharma and will focus on leveraging the company's pioneering cloud-based genomics platform to drive clinical impact, working closely with management and engineering teams, and with external partners and collaborators.
TBPH: 17.07 (-0.37)

Theravance/Glaxo Commence Global Late stage Study on COPD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 5:42PM CDT
Glaxo (GSK) and Theravance (THRX) initiated a phase III study in COPD.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)

1 Special Situation Dividend Stock: Snatch Up of Stay Away?
David Williamson, The Motley Fool - Motley Fool - Sun Jul 13, 11:52AM CDT
Biotech Theravance  (NASDAQ: THRX) is undergoing a radical transformation. Is this special situation a unique opportunity for dividend investors, or arre problems lurking beneath the surface. Theravance recently split in two, with the money it...
THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16)

Glaxo/Theravance Drug Gets Japanese Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:00AM CDT
Glaxo (GSK) and Theravance's (THRX) Anoro Ellipta has been approved in Japan.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13), REGN: 377.84 (+0.90)

Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
ACT: 245.91 (-4.47), CLDX: 13.42 (-0.06), PTCT: 40.24 (-1.93), GALE: 1.95 (-0.09), TBPH: 17.07 (-0.37), FRX: 99.00 (-0.77)

Glaxo/Theravance Seek to Expand Breo Ellipta's Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 10:50AM CDT
Glaxo (GSK) and Theravance (THRX) are looking to get Breo Ellipta approved for asthma in the U.S.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13), REGN: 377.84 (+0.90)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile's Starlink Satellite Service Beta is Now Open for Signup

Updated Category News Views 270

T-Mobile Introduces Registration for Starlink Beta Program T-Mobile US, Inc. (NASDAQ: TMUS) has recently opened registrations for its much-anticipated beta program for Starlink, a direct-to-cell satellite service aimed at enhancing connectivity. This service promises to bridge the gaps in network coverage across vast areas of the United States, specifically targeting dead...

Continue Reading
WAVJA's Innovative Energy System Set to Change Indoor Power

Updated Category News Views 342

WAVJA's Photon Energy System Overview The energy landscape is undergoing significant changes, and WAVJA is at the forefront with its groundbreaking Photon Energy System (PES). This U.S.-based innovation is not just about powering homes; it's revolutionizing how we think about renewable sources of energy. In a time where climate challenges are prevalent, PES transforms the...

Continue Reading
Kipling Unveils New Collections at Exclusive London Event

Updated Category News Views 333

Kipling Launches Exciting New Collection in London Recently, Kipling captivated the fashion world by hosting an innovative and exclusive event in London. This gathering celebrated the unveiling of their latest collection, G.rilla Girlz, and brought a nostalgic touch by showcasing some of the brand's most iconic designs. A Night to Remember at Village Underground The event...

Continue Reading
Transforming TV Experiences: Cerence Renews Voice Interaction with LG

Updated Category News Views 159

Enhancing LG TVs with Conversational AI In a significant leap towards improved user experience, Cerence Inc. (NASDAQ: CRNC) has partnered with LG Electronics Inc. to integrate advanced voice interaction technology into LG's global television lineup. This innovative collaboration harnesses Cerence’s cloud-based neural text-to-speech (TTS) technology, enriching the way...

Continue Reading
Exciting Prize Opportunities as Bybit Welcomes New Traders to WSOT

Updated Category News Views 40

Bybit Enhances Participation Incentives for WSOT 2024 Bybit, a leading cryptocurrency exchange, is thrilled to announce an enticing prize opportunity aimed at encouraging last-minute participants in the World Series of Trading (WSOT) 2024. This newly implemented initiative allows late entrants to access a dedicated prize pool of 100,000 USDT. This bonus pool is designed...

Continue Reading